Sanofi to buy US drugmaker for over $9 billion
French pharmaceutical company Sanofi is acquiring biopharmaceutical company Blueprint Medicines, a U.S. developer of drugs for the treatment of rare autoimmune diseases, for more than $9 billion, according to Sanofi’s website.
Sanofi will pay $129 per share, totaling about $9.1 billion, when the deal closes in the third quarter, and up to $400 million in additional cash if certain conditions are met.
As part of the deal, the French company will receive, among other things, the rights to Ayvakit, the only drug approved in the United States and the European Union to treat mastocytosis, a rare immunological disease.
Ayvakit generated $479 million in revenue last year. It sold $150 million of it in the first quarter of this year, an increase of more than 60 percent year-on-year.
Sanofi’s share price was down 1.15 percent at the end of the first hour of trading on the Paris Stock Exchange on Monday.
Visszajelzés küldése
Oldalsó panelek
Előzmények
Mentve
Related news
New Communications Manager at Novartis Hungary
🎧 Hallgasd a cikket: Lejátszás Szünet Folytatás Leállítás Nyelv: Auto…
Read more >Sanofi Budapest Hub strengthens innovation and future-proofing with expanded office
🎧 Hallgasd a cikket: Lejátszás Szünet Folytatás Leállítás Nyelv: Auto…
Read more >BENU’s new initiative calls for responsible management of expired or unused medicines
🎧 Hallgasd a cikket: Lejátszás Szünet Folytatás Leállítás Nyelv: Auto…
Read more >Related news
Campaign about the sustainability of meat consumption
🎧 Hallgasd a cikket: Lejátszás Szünet Folytatás Leállítás Nyelv: Auto…
Read more >The customer of the future in 2025: price and convenience above all else
🎧 Hallgasd a cikket: Lejátszás Szünet Folytatás Leállítás Nyelv: Auto…
Read more >E-commerce balance in the red
🎧 Hallgasd a cikket: Lejátszás Szünet Folytatás Leállítás Nyelv: Auto…
Read more >
